|
<br />C-1
<br />
<br />
<br />EXHIBIT C
<br />Injunctive Relief
<br />A. Definitions Specific to this Exhibit
<br />1. “Cancer-Related Pain Care” means care that provides relief from pain resulting
<br />from a patient’s active cancer or cancer treatment as distinguished from treatment
<br />provided during remission.
<br />2. “Janssen” means Johnson & Johnson, Johnson & Johnson Innovative Medicine,
<br />Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc., and
<br />Janssen Pharmaceutica, Inc. (collectively, “Janssen”), including all of their
<br />subsidiaries, predecessors, successors, current officers, directors, employees,
<br />representatives, agents, affiliates, parents, and assigns acting on behalf of Janssen in
<br />the United States.
<br />3. “End-of-Life Care” means care for persons with a terminal illness or at high risk for
<br />dying in the near future in hospice care, hospitals, long-term care settings, or at
<br />home.
<br />4. “Health Care Provider” means any U.S.-based physician or other health care
<br />practitioner who is licensed to provide health care services or to prescribe
<br />pharmaceutical products and any medical facility, practice, hospital, clinic, or
<br />pharmacy.
<br />5. “In-Kind Support” means payment or assistance in the form of goods, commodities,
<br />services, or anything else of value.
<br />6. “Lobby” and “Lobbying” shall have the same meaning as “lobbying activities” and
<br />“lobbying contacts” under the federal lobbying disclosure act, 2 U.S.C. § 1602 et
<br />seq., and any analogous state or local provisions governing the person or entity being
<br />lobbied. As used in this document, “Lobby” and “Lobbying” include Lobbying
<br />directly or indirectly, through grantees or Third Parties.
<br />7. “Opioid(s)” means all naturally occurring, synthetic, or semisynthetic substances that
<br />interact with opioid receptors and act like opium. For the avoidance of doubt, the
<br />term “Opioid(s)” does not include Imodium.
<br />8. “Opioid Product(s)” means all current and future medications containing Opioids
<br />approved by the U.S. Food & Drug Administration (FDA) and listed by the DEA as
<br />Schedule II, III, or IV drugs pursuant to the federal Controlled Substances Act
<br />(including but not limited to buprenorphine, codeine, fentanyl, hydrocodone,
<br />hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone,
<br />tapentadol, and tramadol). The term “Opioid Products(s)” shall not include (i)
<br />methadone and other substances when used exclusively to treat opioid abuse,
<br />addiction, or overdose; or (ii) raw materials, immediate precursors, and/or active
|